ACTRN12617001564347已完成1 期
A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally in Healthy Male Adult Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pharmaxis
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- Male
入选标准
- •Healthy males, aged between 18 and 60 years (inclusive).
- •2. Eligibility of the subjects will be based on clinical history, physical examination, ECG and Lab results
- •3. BMI between 18.5 kg/m2 and 30.0 kg/m2 inclusive.
- •4. No clinically relevant abnormality in an ECG; QTcF (Fredericia’s corrected QT) > or equals to 450 ms, PR interval of 120-210 ms and a QRS duration < or equals to 120 ms.
- •5. Adequate venous access in the left or right arm to allow collection of a number of blood samples.
- •6. Male subjects with female partners of childbearing potential may be enrolled if they:
- •a. are documented to be surgically sterile (vasectomy at least six months prior to dosing), or
- •b. practice true abstinence for 30 days after the study drug administration, or
- •c. agree to use a barrier method of contraception (e.g. condom) from Screening and until 30 days after administration of the study. Additionally, the female partner must use a highly effective hormonal method, such as birth control pills, patches, implants or injections; or use an intra uterine device (IUD).
- •Contraceptive requirements do not apply to subjects who are exclusively in same-sex relationships.
- •7. Have given written informed consent to participate in this study in accordance with local regulations.
排除标准
- •Clinically significant abnormal findings on the physical examination, medical history, ECG or laboratory results as deemed by the PI (or delegate).
- •2. Clinically significant gastrointestinal, renal, hepatic, neurologic, haematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, skin or cardiovascular disease or any other condition, which, in the opinion of the PI (or delegate), would jeopardise the safety of the subject or impact the validity of the study results.
- •3. History of significant drug allergies or significant allergic reaction or currently suffers from clinically significant systemic allergic disease. Mild hay fever is acceptable.
- •4. Evidence of abnormal wound healing (e.g. hypertrophic scars) as the result of surgery or trauma as deemed by the PI or delegate.
- •5. Have received or is anticipated to receive any prescription systemic or topical medication, or any over the counter, complimentary or alternative medicine 7 days prior to the start of dosing or within 5 half-lives of the drug whichever is longer (excluding paracetamol).
- •6. Systolic BP <90 or >140 mmHg, diastolic BP <40 or >90 mmHg and HR <40 or >100 beats per minute (BPM).
- •7. ALT, AST or bilirubin >1.5x ULN.
- •8. Gilbert’s syndrome sufferers are not eligible.
- •9. Evidence of significant renal insufficiency, as indicated by an estimated creatinine clearance using the Cockcroft-Gault formula of less than 80 mL/min at Screening.
- •10. Positive Screening test for Hepatitis B surface antigen or Hepatitis C antibody or human immunodeficiency virus (HIV)
- •11. Any condition directly or indirectly caused by or associated with Transmissible Spongiform Encephalopathy (TSE) Creutzfeldt-Jakob Disease (CJD) variant Creutzfeldt-Jakob Disease (vCJD) or new variant Creutzfeldt-Jakob Disease (nvCJD)
- •12. History of drug abuse in the last 2 years
- •Males who regularly drink more than four (4) units of alcohol daily (1 unit = 285 mL beer (4.9% Alc./Vol), 100 mL wine (12% Alc./Vol), 30 mL spirit (40% Alc./Vol)).
- •Used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff) within 6 weeks before screening and unable to abstain from using these products until study completion.
- •15. Unable to abstain from consuming caffeine and/or xanthine products (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) for defined periods (e.g., for at least 48 hours prior to admission to the clinical facility, and whilst confined to the clinical facility).
- •16. Consumption of:
- •a. Grapefruit, grapefruit juice, star fruit, oranges, orange juice, Seville oranges (CYP450 enzymes) within 7 days prior to administration of the study drug.
- •b. Poppy seeds and poppy seed products within 7 days prior to administration of the study drug.
- •c. Alcohol within 48 hours prior to administration of study drug and during the conduct of the study.
- •17. Positive urine screen for drugs of abuse and alcohol breath test at screening and study check-in. Subjects may undergo a repeat urine drug screen or alcohol breath test at the discretion of the PI (or delegate).
- •18. Receipt of blood or blood products, or loss or donation of 450 mL or more of blood within 90 days before the first dose administration.
- •19. Any condition that would interfere with drug absorption (e.g. chronic diarrhoea).
- •20. Have participated in a clinical trial or have received an experimental therapy within 3 months or 5 half-lives of the drug, whichever is the longer, prior to dosing.
- •21. Clinicall
研究者
相似试验
已完成
1 期
A Single Ascending Dose and Multiple Ascending Dose Phase 1 Study of PXS-5505A Administered Orally in Healthy Adult MalesACTRN12619000332123Pharmaxis Ltd56
已完成
1 期
A study of the safety and pharmacokinetics and pharmacodynamics of the LOXL2 inhibitor PXS-5338K in healthy male subjects given single and repeated doses.ACTRN12617001444370Pharmaxis Ltd72
已完成
1 期
First-in-Human Study of RLYB116 in Healthy Participantscomplement mediated diseasesBlood - Haematological diseasesInflammatory and Immune System - Autoimmune diseasesACTRN12621001571864IPC Research, LLC89
已完成
1 期
Single Ascending Dose and Multiple Ascending Dose Phase I study of PXS-4728A Administered Orally in Healthy Adult Males.Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary diseaseRespiratory - Other respiratory disorders / diseasesCystic FibrosisACTRN12614001326684Pharmaxis Ltd.72
已完成
1 期
A Phase I Single-Ascending Dose and Multiple-Ascending Dose Study of RO6889450 in Healthy Japanese MaleHealthy adultsJPRN-jRCT2080224516Chugai Pharmaceutical Co., Ltd.64